

FL-rFVIII than the cost for using the BDD-rFVIII product. Over a typical lifetime of 70 years, the difference would yield over 135, 000 SEK in annual cost savings per patient. The authors noted that lowering the price per IU of the BDD-rFVIII product resulted in the same trend for cost-savings with FL-rFVIII.

Conclusion. The results of the analysis of the evidence base showed that Recombinant preparation of the third generation «Advate» is effective for patients with severe or moderately severe hemophilia A. Treatment of «Adwate» instead of «Refacto AF» will result in more annual savings per patient than 135,000 Swedish crowns on condition of average life expectancy of patients with hemophilia - 70 years.

RESEARCH OF ECONOMIC AVAILABILITY OF HOMEOPATHIC MEDICINES IN UKRAINE

V. M. Tolochko, V. Iu. Adonkina

Department of Management and Economics of Pharmacy

Institute of Pharmacy Professionals Qualification Improvement, Kharkiv, Ukraine

uef-ipksf@nuph.edu.ua

Introduction. In recent years, in Ukraine, there has been an increase in attention to non-traditional methods of treatment, in particular to homeopathy, which syands out from all known medical systems by its special understanding of the disease and the way of its treatment.

The aim of the study is the determination of economic availability of ready-made homeopathic medicines (HoM) in the pharmaceutical market of Ukraine.

Materials and methods of research. The research of economic availability of HoM were analyzed according to the State Register of Medicinal Products.

Results of research. In the course of the analysis, it was found that the most (91.4%) of ready-made HoM, which are registered in Ukraine, have the solvency adequacy ratio (Ca.s. < 5), which confirms their high availability for the average resident of Ukraine. The group of moderately available included 14 ready-made HoM (8.0%) from

various pharmacotherapeutic groups: «Liver therapy»; «Various alimentary tract and metabolism products»; «Other cardiac combination products»; «Other gynecologicals»; «Other urologicals»; «Other drugs for disorders of the musculo-skeletal system»; «Other nervous system drugs»; «All other therapeutic products». One medicine was allocated among all the others – Nigersan D5 (Kehlbeck, Germany), which belongs to the subgroup L03AX – «Other immunostimulants» and is used for isopathic treatment of a tuberculin constitution and its secondary diseases, which has a solvency adequacy ratio (Ca.s. >15), which characterizes it as a little available medicine for the average resident of Ukraine.

Conclusion. Thus, according to the results of the economic availability analysis, it was found that the overwhelming majority of ready-made HoM presented in the pharmaceutical market are available to patients who prefer non-traditional treatments.